Metüülfenidaat

Metüülfenidaat (kaubanimega Ritalin, Concerta jt) on kesknärvisüsteemi stimulant (fenüülalküülamiin), mida kasutatakse peamiselt aktiivsus- ja tähelepanuhäire (ATH) raviks. Harvem on sellega ravitud ka narkolepsiat.

ATH ravil on selle efektiivsust hinnatud võrdseks atomoksetiiniga ja veidi väiksemaks võrreldes amfetamiiniga.

Üksikutel juhtudel võib ravimi kasutajatel välja kujuneda ravimisõltuvus, see oht on aga tunduvalt väiksem kui amfetamiini puhul.

Eestis kasutatakse seda tänapäeval ainult aktiivsus- ja tähelepanuhäire korral, kuid varem on kasutatud ka apatiko-abuulilise sündroomiga haigete aktiveerimiseks või muu asteenia või loiduse korral.

Viited

  1. ↑ Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V (mai 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology. 30 (5): 444–458. DOI:10.1177/0269881116636105. PMID 27005307. S2CID 104938.
  2. ↑ Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (november 2011). "Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis". Journal of Attention Disorders. 15 (8): 674–683. DOI:10.1177/1087054710379737. PMID 20837981. S2CID 43503227.
  3. ↑ Hanwella R, Senanayake M, de Silva V (november 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry. 11 (1): 176. DOI:10.1186/1471-244X-11-176. PMC 3229459. PMID 22074258.
  4. ↑ Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B (10. veebruar 2016). "Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis". Medical Journal of the Islamic Republic of Iran. 30: 325. PMC 4898838. PMID 27390695.
  5. ↑ Stuhec M, Lukić P, Locatelli I (veebruar 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. DOI:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
  6. ↑ Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (juuni 2001). "Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology". Journal of Child and Adolescent Psychopharmacology. 11 (2): 171–180. DOI:10.1089/104454601750284081. PMID 11436957. Mall:ProQuest.
  7. ↑ Faraone SV, Biederman J, Roe C (oktoober 2002). "Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis". Journal of Clinical Psychopharmacology. 22 (5): 468–473. DOI:10.1097/00004714-200210000-00005. PMID 12352269. S2CID 19726926.
  8. ↑ Faraone SV, Buitelaar J (aprill 2010). "Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis". European Child & Adolescent Psychiatry. 19 (4): 353–364. DOI:10.1007/s00787-009-0054-3. PMID 19763664. S2CID 9447892.

Allikad